Enhanced ocular neuroprotection and neurostimulation

• US 7,833,966 B2
• Filed: 11/21/2006
• Issued: 11/16/2010
• Est. Priority Date: 07/18/2005
• Status: Expired due to Fees

• Current Assignee: Minu, LLC, Optivue LLP
• Original Assignee: Minu, LLC, Optivue LLP
• Inventors: Peyman, Gholam A.
• Primary Examiner(s): Kemmerer; Elizabeth C.
• Assistant Examiner(s): Emch; Gregory S
• Application Number:
  US11/561,912
• Publication Number:
  US 20070078077A1
• Time in Patent Office: 1,456 Days
• Field of Search: None
• US Class Current: 514/20.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 38/204 IL-6
• CPC Class Codes: A61K 38/2093 Leukaemia inhibitory factor [LIF]
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed.

Claims

1. A method of enhancing the rate of restoration of corneal sensitivity in an eye of an individual after refractive surgery, the method comprising

topically administering cyclosporine to an eye of an individual having loss of corneal sensation after refractive surgery on the eye under conditions of at least daily dosing intervals in a therapeutic regimen for a duration sufficient to provide an enhanced rate of restoration of corneal sensitivity in the individual after refractive surgery, and assessing the enhanced rate of restoration of post-surgical corneal sensitivity.

2. The method of claim 1 wherein cyclosporine is administered at least substantially immediately after surgery and at least daily for up to at least one week after surgery.

3. The method of claim 1 wherein the restoration rate of post-surgical corneal sensitivity is enhanced compared to an eye not receiving cyclosporine.

4. The method of claim 1 wherein cyclosporine is administered starting at least on the day of surgery.

5. The method of claim 1, wherein the surgery is selected from laser-assisted in situ keratomileusis, laser-assisted in situ epithelial keratomileusis, and photorefractive keratectomy.

6. The method of claim 1, wherein the cyclosporin is administered as an emulsion having cyclosporine in a concentration ranging from 0.01% w/v to 1.0% w/v.

7. The method of claim 6, wherein the cyclosporin is administered at a concentration of 0.01% w/v.

8. The method of claim 6, wherein the cyclosporin is administered at a concentration of 0.05% w/v.

9. The method of claim 1, wherein the cyclosporin is administered as a solution having cyclosporine in a concentration ranging from 0.01% w/v to 1.0% w/v.

10. The method of claim 9, wherein the cyclosporin is administered at a concentration of 0.01% w/v.

11. The method of claim 9, wherein the cyclosporin is administered at a concentration of 0.05% w/v.

12. A method of enhancing the rate of restoration of corneal sensitivity, the method comprising

topically administering cyclosporine to an eye of an individual having loss of corneal sensation after refractive surgery on the eye,

and assessing the enhanced rate of restoration of post-surgical corneal sensitivity.

13. The method of claim 12, wherein the cyclosporin is administered as an emulsion having cyclosporine in a concentration ranging from 0.01% w/v to 1.0% w/v.

14. The method of claim 13, wherein the cyclosporin is administered at a concentration of 0.01% w/v.

15. The method of claim 14, wherein the cyclosporin is administered at a concentration of 0.05% w/v.

16. The method of claim 12, wherein the cyclosporin is administered as a solution having cyclosporine in a concentration ranging from 0.01% w/v to 1.0% w/v.

17. The method of claim 16, wherein the cyclosporin is administered at a concentration of 0.01% w/v.

18. The method of claim 17, wherein the surgery is selected from laser-assisted in situ keratomileusis, laser-assisted in situ epithelial keratomileusis, and photorefractive keratectomy.

19. The method of claim 16, wherein the cyclosporin is administered at a concentration of 0.05% w/v.